FibroGen (FGEN) announced that it will implement a 1-for-25 reverse stock split of its issued and outstanding common stock, effective at 5:00 p.m. Eastern Time on June 16. FibroGen’s common stock will begin trading on a split-adjusted basis on June 17, when the markets open, under the company’s existing trading symbol.
Confident Investing Starts Here:
- Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks right to your inbox with TipRanks' Smart Value Newsletter
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on FGEN:
- FibroGen Amends Financing Agreement for Flexibility
- FibroGen’s Earnings Call: Strategic Gains Amid Revenue Woes
- FibroGen’s Strategic Positioning and Financial Health: A Buy Rating Backed by Strong Cash Reserves and Promising Clinical Pipeline
- FibroGen Reports Q1 2025 Earnings and Strategic Updates
- Is FGEN a Buy, Before Earnings?
Looking for a trading platform? Check out TipRanks' Best Online Brokers guide, and find the ideal broker for your trades.
Report an Issue